transmitting signals from ligand-activated receptor tyrosine kinases [1] [2] [3] [4] [5] . Class I PI3Ks catalyze phosphorylation of phosphatidylinositol 4, 4, , which binds to AKT and PDK1 at the plasma membrane. AKT is activated by phosphorylation by PDK1 at T308
and by mTOR/Rictor (TORC2) at S473. AKT promotes cell survival and proliferation by phosphorylation of GSK3α/β, FoxO, MDM2, BAD, and p27
KIPI [6] . AKT also activates the mTOR/Raptor (TORC1) complex which regulates protein synthesis and cell growth [7] .
Mutations in PIK3CA, the gene that encodes the p110α class IA PI3K catalytic subunit are present in a variety of cancers that arise in adults [4, 8] . The PTEN phosphatase modulates PIP3 activity and has been identified as a tumor suppressor that is frequently inactivated in cancer by gene mutation and/or deletion and by promoter methylation [9, 10] . Tyrosine kinase oncogenes (e.g., Bcr-Abl, HER2, MET, KIT, and others) are strong activators of the PI3K pathway [11] . Thus, inhibition of PI3K offers an attractive molecular target for cancer therapy with the potential for being synergistic with drugs targeting RTK's [12] .
A number of PI3K antagonists have been developed, all of which are ATP mimetics that act by binding reversibly to the ATP pocket of PI3K p110 [5] . SAR245408 is one such pan-PI3K inhibitor that has shown activity against breast, lung, and prostate cancer xenografts [5] . It has shown an acceptable toxicity profile as a single agent in an adult phase I study that also demonstrated an objective partial response and evidence of stable disease [13] . The NCI Pediatric Preclinical Testing Program (PPTP) has previously tested agents acting against other components of the PI3K signaling pathway, including rapamycin [14, 15] , the mTOR kinase inhibitor AZD8055 [16] , and the AKT inhibitors GSK690693 and MK-2206 [17,18] , all of which showed modest in vivo activity against the PPTP models. Here we report the evaluation of SAR245408 against the PPTP in vitro and in vivo (xenograft) models of childhood cancers. 
MATERIALS AND METHODS:
In vitro testing: In vitro testing was performed using DIMSCAN, a semiautomatic fluorescence-based digital image microscopy system that quantifies viable (using fluorescein diacetate [FDA] ) cell numbers in tissue culture multiwell plates [19] . Cells were incubated in the presence of agent for 96 hours at concentrations from 10 nM to 100 µM with replicates of 6-12 for each concentration evaluated. value is used (larger values connote greater sensitivity). The lowest T/C% value is the Y min .
In vivo tumor growth inhibition studies: CB17SC scid -/-female mice (Taconic Farms, Germantown NY), were used to propagate subcutaneously implanted kidney/rhabdoid tumors, sarcomas (Ewing, osteosarcoma, rhabdomyosarcoma), neuroblastoma, and non-glioblastoma brain tumors, while BALB/c nu/nu mice were used for glioma models, as previously described [21] . Human leukemia cells were propagated by intravenous inoculation in female non-obese diabetic (NOD)/scid -/-mice as described previously [22] . Female mice were used irrespective of the patient gender from which the original tumor was derived. All mice were maintained under barrier conditions and experiments were conducted using protocols and conditions approved by the institutional animal care and use committee of the appropriate consortium member. Eight to ten mice were used in each control or treatment group. 
Statistical Methods:
The exact log-rank test, as implemented using Proc StatXact for SAS®, was used to compare event-free survival distributions between treatment and control groups. P-values were two-sided and
were not adjusted for multiple comparisons given the exploratory nature of the studies.
Drugs and Formulation: SAR245408 was provided to the Pediatric Preclinical Testing Program by Exelixis Inc., through the Cancer Therapy Evaluation Program (NCI). Powder was stored at room temperature, protected from light. Drug was formulated in 10 mM HCl, in sterile water for injection, sonicated to form a fine suspension, and made fresh prior to administration. SAR245408 was administered orally (PO) at 100 mg/kg to mice using a daily schedule for 14 days, with a further 4 weeks of observation. SAR245408 was provided to each consortium investigator in coded vials for blinded testing.
RESULTS
In vitro testing: SAR245408 demonstrated cytotoxic activity, with Y min values approaching 0% for all of the cell lines at the highest concentration tested (100 µM). The median relative IC 50 (rIC 50 ) value for the PPTP cell lines was 10.9 µM, with a range from 2.7 µM (CHLA-10) to 24.5 µM (TC-71), Table I . There were no significant differences by histotype in median rIC 50 values, though there was a trend for lower values for the rhabdomyosarcoma panel (median rIC 50 5.6 µM) and higher values for the neuroblastoma panel (median rIC 50 19.5 µM). A metric used to compare the relative responsiveness of the PPTP cell lines to SAR245408 is the ratio of the median rIC 50 of the entire panel to that of each cell line, Figure 1 . Higher ratios are indicative of greater sensitivity to SAR245408 and are shown in the figure by bars to the right of the midpoint line. Figure 1 illustrates the higher sensitivity for the rhabdomyosarcoma cell lines and the lower sensitivity for the neuroblastoma cell lines.
In vivo testing: SAR245408 was tested against the PPTP xenografts using a dose of 100 mg/kg administered orally daily for 14 days. The total planned observation period was 6 weeks. SAR245408 was well tolerated, with only 0.7% toxicity rate in the treated groups, similar to that observed for control animals. All 44 tested xenograft models were considered evaluable for efficacy. A complete summary of results is provided in The gene expression pattern of Class I PI3K isoforms is shown in Figure 4A . There is less variation in expression for PIK3CA than for other isoforms, and its expression is highest for the osteosarcoma and ALL xenografts and is lower for the rhabdomyosarcoma xenografts. PIK3CB is expressed at highest levels in low grade (BT-35 and BT-40) and high-grade glioma xenografts (e.g., GBM2 and BT-39). The most striking observation is the pattern of expression of PIK3CD, which is virtually restricted to the ALL and lymphoma cell lines and xenografts, as would be expected from the hematopoietic cell specificity of this isoform in normal tissues [24] . Phospho-AKT and PTEN expression for solid tumor xenografts are shown in Figure 4B .
Supplemental
Phospho-AKT is detectable for many xenografts in the PPTP solid tumor panels, while PTEN low expression (consistent with PTEN deletion) is uncommon. Given the small number of solid tumor xenografts with EFS T/C values > 2 and the lack of objective responses, it is not possible to relate phospho-AKT levels to SAR245408 activity. Phospho-AKT levels are not distinctive for the 4 xenografts with EFS T/C > 2 (KT-16, Rh41, Rh18, and NB-EBc1) compared to the remaining xenografts. . The lack of objective responses is consistent with a cytostatic effect of SAR245408. However, it is also possible that some effects observed in vivo were due to SAR245408 acting on the tumor microenvironment.
The PIK3CD specific inhibitor GS-1101 (CAL-101) has shown preclinical and clinical activity against adult lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), but its activity in ALL is not yet defined [26] . SAR245408 shows approximately equal enzyme inhibitory activity against PIK3CA and PIK3CD [25, 27] . Future research will be required to determine whether a lack of remission-inducing in vivo activity against PIK3CD-expressing ALL xenografts in this study is the result of failure to achieve sufficiently high and prolonged levels of PIK3CD inhibition or is the result of intrinsic resistance of the ALL xenografts to PIK3CD inhibition.
The role of PI3K/AKT in childhood cancers is not well defined, though there is evidence that the pathway is activated in some pediatric malignancies [18, 28] . For example, high phosphorylation levels of Akt(S473) were associated with poor overall and poor disease-free survival for rhabdomyosarcoma patients [29] , and activation of PI3K signaling has been reported for neuroblastoma [30] [31] [32] and medulloblastoma [33] [34] [35] . However, whole exome and/or whole genome sequencing applied to approximately 100 high-risk neuroblastoma tumor specimens did not identify recurring mutations in PI3K pathway genes [36, 37] . Likewise, recurring genomic F o r P e e r R e v i e w 8 alterations in PI3K pathway genes appear to be uncommon in high-risk B-precursor ALL cases [38] . A targeted mutation screen identified PIK3CA mutations in 5% (3/60) of embryonal rhabdomyosarcoma cases, but mutations were not seen in the neuroblastoma (n=192), Ewing sarcoma (n=75), or alveolar rhabdomyosarcoma (n=29) specimens evaluated [39] , Additionally, mutations in PIK3R1 were not observed [39] . PIK3CA mutations are also uncommon in medulloblastoma tumor specimens [40] [41] [42] . As genomic alterations in target genes have been the most reliable predictor of robust antitumor activity for molecularly targeted agents, the paucity of mutations in PI3K family genes reported for pediatric cancers argues against the expectation of single agent in vivo activity for PI3K inhibitors in the pediatric setting, consistent with our findings.
The current study suggests that a development plan for SAR245408 as a single agent for pedatric cancers should employ a focused approach. As more is learned about the role of the PI3K pathway in pediatric cancers, it may become possible to identify selected subsets of childhood cancers that may be highly responsive to PI3K inhibitors as single agents, including subsets not represented in the current PPTP in vitro and in vivo models. Additional research opportunities for future pediatric preclinical evaluations of SAR245408
include evaluating it in combination with other therapies [43] .
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The authors consider that there are no actual or perceived conflicts of interest. value is the mean RTV for the treatment group divided by the mean RTV for the control group. High activity = T/C < 0.15; Intermediate activity = T/C < 0.45 but > 0.15; and Low activity = T/C > 0.45. 2 Objective response measures are described in detail in the Supplemental Response Definitions. PD1 = progressive disease with EFS T/C ≤ 1.5, and PD2 = progressive disease with EFS T/C > 1.5. 3 EFS T/C values = the ratio of the median time to event of the treatment group and the median time to event of the respective control group. High activity requires: a) an EFS T/C > 2; b) a significant difference in EFS distributions, and c) a net reduction in median tumor volume for animals in the treated group at the end of treatment as compared to at treatment initiation. Intermediate activity = criteria a) and b) above, but not having a net reduction in median tumor volume for treated animals at the end of the study. Low activity = EFS T/C < 2. 
Response and Event Definitions for Solid Tumor Xenograft Models
Response: For individual mice, progressive disease (PD) was defined as < 50% regression from initial volume during the study period and > 25% increase in initial volume at the end of study period.
Stable disease (SD) was defined as < 50% regression from initial volume during the study period and ≤ 25% increase in initial volume at the end of the study. Partial response (PR) was defined as a tumor volume regression ≥50% for at least one time point but with measurable tumor ( ≥ 0.10 cm For each individual mouse that had PD and had an event in the treatment groups, a TGD value was calculated by dividing the time to event for that mouse by the median time to event in the respective control group. Median times to event were estimated based on the Kaplan-Meier event-free survival distribution. If a mouse had a TGD value ≤ 1.5, that mouse was considered PD1. If the TGD value was > 1.5, the mouse was considered PD2. Mice that had PD but did not have an event at the end of the study were coded as PD2.
Event-free survival:
An event in the solid tumor xenograft models was defined as a quadrupling of tumor volume from the initial tumor volume. Event-free survival was defined as the time interval from initiation of study to the first event or to the end of the study period for tumors that did not quadruple in volume. The time to event was determined using interpolation based on the formula: t and e V is the event threshold (4 times initial tumor volume for solid tumor xenografts).
Response and Event Definitions for Acute Lymphoblastic Leukemia (ALL) Xenograft

Models
Individual mice were categorized as PD if their percentage of hCD45 cells never dropped below 1% and they had an event before the end of the study period. An event is defined as hCD45 cells above 25% in the peripheral blood with times to event calculated as above. Individual mice were hCD45 was less than 1% for the last three measurements of the study. For treatment groups, PD was further classified into PD1 and PD2 according to the TGD value.
The time to event was determined using interpolation based on the formula: t and e V is the event threshold (25% for ALL xenografts).
Summary statistics and analysis methods
Overall Group Response: Each individual mouse was assigned a score from 0 to 10 based on their response: PD1=0, PD2=2, SD=4, PR=6, CR=8, and MCR=10, and the median for the group determined the overall response. Studies in which toxicity was greater than 25% or in which the control group was not at least SD, were considered inevaluable and were excluded from analysis. was greater than one-half of the study period or in which the median EFS for the control line did not exist are considered not evaluable for the EFS T/C measure of activity. 
